Japan Tobacco to launch Ploom X Advanced HTP device in South Korea by year-end

Oct.24.2024
Japan Tobacco to launch Ploom X Advanced HTP device in South Korea by year-end
Japan Tobacco's South Korean subsidiary plans to unveil its latest HTP device, the "Ploom X Advanced", at a press conference on 28 October, with a launch expected by the end of the year. This will be the company's first attempt to re-enter the South Korean HTP market after a three-year hiatus.

Japan Tobacco Korea Corporation (JT) plans to unveil its latest heated tobacco product (HTP) device, "Ploom X Advanced", at a press conference on 28 October, according to a recent report by M.Dnews. The company expects to launch the product by the end of this year, marking its return to the South Korean HTP market after a three-year hiatus.

 

The latest product to be launched by JT in 2023 is 'Ploom'. According to the company's statistics, in the first half of this year, sales of "Ploom" in the Japanese market increased by approximately 36% year-on-year, exceeding the growth rate of local market demand.

 

JT Korea launched Ploom Tech in 2019 in an attempt to enter the Korean market, but it has not been successful. The market is currently dominated by Korean tobacco company KT&G and the Korean arm of Philip Morris International, with market shares of 45.8% and 20% respectively. British American Tobacco (BAT) has a 10.4% share of the HTP market in Korea.

 

According to the South Korean Ministry of Strategy and Finance, sales of traditional cigarettes totalled 3 billion packs last year, down 2.8% from the previous year. However, sales of HTP products increased by 12.6% to 610 million packs.

 

Industry experts predict that JT Korea will develop more detailed market strategies after its comeback in order to secure a place in the highly competitive market. An industry insider said, "With the re-entry of JT Korea, the HTP market in Korea will have more opportunities for development.
 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Aurora advances retail tobacco licensing ordinance to curb under-21 access to vapes and tobacco
Aurora advances retail tobacco licensing ordinance to curb under-21 access to vapes and tobacco
The Denver Post reported that Aurora’s City Council unanimously approved a retail tobacco licensure ordinance on first reading Monday night to reduce underage access to tobacco products, including e-cigarettes and vaping cartridges. The ordinance would stiffen fines for businesses that sell to people under 21 and tighten rules on where tobacco retailers can locate in the city.
Feb.26 by 2FIRSTS.ai
Russia’s Duma Deputy Speaker Davankov calls for a total vape ban, citing drug sales disguised as vapes
Russia’s Duma Deputy Speaker Davankov calls for a total vape ban, citing drug sales disguised as vapes
Vladislav Davankov, deputy speaker of Russia’s State Duma, urged a nationwide ban on vapes, arguing it would help prevent drugs being sold under the cover of vaping products, including near schools. The remarks come as Russia prepares to enforce a separate ban on vape sales at public transport stops starting Sept. 1, 2026.
Feb.09 by 2FIRSTS.ai
Singapore Health Minister Ong Ye Kung receives SEATCA award for tobacco control and anti-vaping push
Singapore Health Minister Ong Ye Kung receives SEATCA award for tobacco control and anti-vaping push
SEATCA has honoured Singapore Health Minister Ong Ye Kung with its inaugural Trailblazer Award, citing Singapore’s long-standing vaping ban, stepped-up enforcement and regulatory measures, and the city-state’s role in sharing tobacco-control policy experience across ASEAN.
Feb.06 by 2FIRSTS.ai
Japan Tax Reform Threatens JTI Heated Tobacco Growth in 2026
Japan Tax Reform Threatens JTI Heated Tobacco Growth in 2026
Japan’s plan to remove the lower tax rate for heated tobacco products could slow growth in the country’s largest HTP market, JTI’s CFO said. Retail prices may rise by 70 to 100 yen, though the company plans phased increases to soften the impact.
JTI
Feb.15
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Global Forum on Nicotine 2026 to explore why prohibition of safer nicotine products risks, and does not protect, public health
Global Forum on Nicotine 2026 to explore why prohibition of safer nicotine products risks, and does not protect, public health
Mar.12